Expertise in
21
conditions

Dr. Melissa M. Hardesty

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
4441 Diplomacy Dr, 
Anchorage, AK 
Accepting New Patients
Offers Telehealth
Expertise in
21
conditions
4441 Diplomacy Dr, 
Anchorage, AK 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Melissa Hardesty is a Gynecologic Oncologist and an Oncologist in Anchorage, Alaska. Dr. Hardesty is highly rated in 21 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Salpingo-Oophorectomy, and Oophorectomy. Dr. Hardesty is currently accepting new patients.

Her clinical research consists of co-authoring 10 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in AK
Hospital Affiliations
Alaska Native Medical Center
Bartlett Regional Hospital
Alaska Regional Hospital
Providence Alaska Medical Center
Mat-Su Regional Medical Center
Languages Spoken
English
Castilian
Spanish
Vietnamese
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Moda Health
  • EPO
  • PPO
Premera
  • EPO
  • PPO

Locations

ALASKA NATIVE TRIBAL HEALTH CONSORTIUM
4441 Diplomacy Dr, Anchorage, AK 99508

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 2
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drugs: Abemaciclib, Letrozole
Study Phase: Phase 2
A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: November 13, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 3 Less Clinical Trials

10 Total Publications

Entrectinib use in a platinum-refractory mucinous ovarian cancer harboring a NTRK3 gene fusion.
Entrectinib use in a platinum-refractory mucinous ovarian cancer harboring a NTRK3 gene fusion.
Journal: Gynecologic oncology reports
Published: February 15, 2023
Similar Doctors
Expertise in
20
conditions
Dr. Joanie M. Hope
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
20
conditions
Dr. Joanie M. Hope
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Alaska Native Tribal Health Consortium

4441 Diplomacy Dr, 
Anchorage, AK 
 (0.1 mi)
907-563-2662
Languages Spoken:
English, French, German, Portuguese
See accepted insurances
Accepting New Patients
Offers Telehealth

Joanie Hope is a Gynecologic Oncologist and an Oncologist in Anchorage, Alaska. Dr. Hope is highly rated in 20 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Salpingo-Oophorectomy, and Oophorectomy. Dr. Hope is currently accepting new patients.

Expertise in
12
conditions
Dr. Kathryn P. Pennington
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
12
conditions
Dr. Kathryn P. Pennington
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Alaska Native Tribal Health Consortium

4320 Diplomacy Dr, 
Anchorage, AK 
 (0.1 mi)
907-265-4955
Languages Spoken:
English, Bosnian, Korean
See accepted insurances
Accepting New Patients
Offers Telehealth

Kathryn Pennington is a Gynecologic Oncologist and an Oncologist in Anchorage, Alaska. Dr. Pennington is highly rated in 12 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Testicular Yolk Sac Tumor, Oophorectomy, and Salpingo-Oophorectomy. Dr. Pennington is currently accepting new patients.

Expertise in
16
conditions
Dr. Thomas J. Burke
Obstetrics and Gynecology | Gynecologic Oncology
Expertise in
16
conditions
Dr. Thomas J. Burke
Obstetrics and Gynecology | Gynecologic Oncology
4320 Diplomacy Dr, 
Anchorage, AK 
 (0.1 mi)
907-729-3100
Languages Spoken:
English, Russian, Spanish, Ukrainian
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Burke is an Obstetrics and Gynecologist and a Gynecologic Oncologist in Anchorage, Alaska. Dr. Burke is highly rated in 16 conditions, according to our data. His top areas of expertise are Cervical Cancer, Endometrial Cancer, Vulvar Cancer, Bladder Reconstruction, and Reconstructive Urology Surgery. Dr. Burke is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hardesty's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 11 Advanced Conditions
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile